Overview

Metformin for HIV Inflammation

Status:
Unknown status
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This proposal seeks to assess the impact of 24 weeks of metformin on non-calcified plaques and calcified plaques assessed by coronary CT angiography, and on whether these changes can be explained by metformin-induced phenotypic and secretory changes of monocytes.
Phase:
Phase 2
Details
Lead Sponsor:
University of Hawaii
Collaborator:
National Institute of General Medical Sciences (NIGMS)
Treatments:
Metformin